Xeraya Capital

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.

Congenica is a biotechnology company based in Cambridge, Cambridgeshire, that specializes in clinical genomics. Founded in 2013, it offers a diagnostic decision support platform known as Sapientia, which integrates human DNA sequences with comprehensive clinical phenotyping. This platform enables clinicians to interpret genetic diseases more effectively by identifying mutations and filtering clinically relevant variants. By facilitating personalized medicine approaches, Congenica supports both clinicians and researchers in advancing patient care and research in the field of genetic diseases.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, founded in 2010 by Drs. John Scandurra and Karl Vollmers. The company specializes in developing an implantable cardiovascular device aimed at treating pulmonary arterial hypertension (PAH). This innovative device is designed to reduce the workload on the right side of the heart, potentially enhancing both survival rates and the quality of life for patients suffering from this condition. Aria CV holds an exclusive license for certain patents from the University of Minnesota, reflecting its strong ties to academic research and innovation in the field of medical devices.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Consumer Physics Inc. is a technology company based in Tel Aviv, Israel, that specializes in the development and distribution of molecular sensors marketed under the SCiO brand. Founded in 2011, the company offers the SCiO, a compact near-infrared spectrometer designed for real-time material analysis. This device connects to smartphone applications and a cloud-based database of material fingerprints, empowering both consumers and businesses to analyze the composition of various materials anytime and anywhere. Consumer Physics also provides a platform for businesses and third-party developers to create custom molecular sensing models and mobile applications. By leveraging the SCiO technology, clients in industries such as food and agriculture can make informed decisions, potentially reducing food waste and enhancing operational efficiency. The company has established strategic partnerships to further its mission and support its innovative offerings.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Boston Neurosciences, Inc. is a medical device company specializing in neurodiagnostics, founded in 2013 and headquartered in Waltham, Massachusetts, with additional offices in Boston and Kaunas, Lithuania. The company has developed a range of ultrasound-based devices that provide non-invasive measurement of intracranial pressure (ICP), cerebral blood flow autoregulation, and intracranial volumetric wave monitoring. Its flagship product, the BNS ICP 3, employs an image-guided, non-invasive approach to measure ICP in real time using ultrasound Doppler technology. These diagnostic methods have undergone clinical testing and validation in leading neuro centers across Europe and the United States. Boston Neurosciences aims to improve patient outcomes in conditions such as traumatic brain injury, concussion, hydrocephalus, stroke, and brain tumors by enabling clinicians to obtain safer, faster, and more accurate measurements of ICP.

ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

PrIME Biologics Pte Ltd. is a Singapore-based biotechnology company focused on the development and manufacturing of therapeutic plasma products. Established in 2010, the company specializes in producing therapeutic Albumin, IVIG, FVIII, FIX, and other plasma-based therapies, including hyperimmune and specialty plasma therapeutics. PrIME Biologics utilizes an innovative manufacturing process known as Preparative Isolation by Membrane Electrophoresis, which enhances product safety by effectively removing viruses, bacteria, endotoxins, and prions. With its state-of-the-art plasma manufacturing facility, PrIME Biologics aims to address the growing demand within the Asian plasma derivative market, which is valued at approximately $1 billion. The company was formerly known as Singapharm Pte Ltd. and rebranded in August 2011, previously operating as a subsidiary of NuSep Holdings Ltd.

Invendo Medical GmbH specializes in the development, manufacturing, and distribution of sterile, single-use, and lightweight robotically-assisted endoscopy products aimed at gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control body, and a supply and processing unit, designed to enhance the endoscopic experience for both patients and healthcare providers. Founded in 2001 and based in Weinheim, Germany, Invendo Medical strives to be a leader in the disposable endoscopy market by focusing on innovation that improves patient compliance and increases the number of procedures performed. The company serves healthcare facilities primarily in the United States and Europe and operates as a subsidiary of Ambu A/S since 2017.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.